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DLP1Alzheimer's disease (AD) exhibits extensive oxidative stress throughout the body, being detected peripherally as
well as associatedwith the vulnerable regions of the brain affected in disease. Abundant evidence not only dem-
onstrates the full spectrum of oxidative damage to neuronal macromolecules, but also reveals the occurrence of
oxidative events early in the course of the disease and prior to the formation of the pathology, which support an
important role of oxidative stress in AD. As a disease of abnormal aging, AD demonstrates oxidative damage at
levels that signiﬁcantly surpass that of elderly controls, which suggests the involvement of additional factor(s).
Structurally and functionally damaged mitochondria, which are more proﬁcient at producing reactive oxygen
species but less so in ATP, are also an early and prominent feature of the disease. Sincemitochondria are also vul-
nerable to oxidative stress, it is likely that a vicious downward spiral involving the interactions between mito-
chondrial dysfunction and oxidative stress contributes to the initiation and/or ampliﬁcation of reactive oxygen
species that is critical to the pathogenesis of AD. This article is part of a Special Issue entitled: Misfolded Proteins,
Mitochondrial Dysfunction and Neurodegenerative Diseases.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is the most prevalent form of dementia
that predominantly affects the elderly populations and is characterized
by selective neuronal death and two pathologic hallmarks, i.e., senile
plaques formed by extracellular deposits of amyloid-β (Aβ) peptides
and neuroﬁbrillary tangles (NFTs) composed of intracellular aggrega-
tions of hyperphosphorylated tau protein [1]. The majority of AD cases
are sporadic. Less than 10% of AD cases are caused by genetic mutations
in three genes including amyloid-β protein precursor (APP), presenilin
1, and presenilin 2, which are involved in the production of Aβ peptide.
Down's syndrome (DS) patients, who carry an extra copy of chromo-
some 21, develop AD-type dementia with pathological hallmarks in
the brain, likely due to the extra copy of the APP gene located on this
chromosome. A vast research effort has beenmade to studyAβ overpro-
duction and/or tau hyperphosphorylation. However, their contributionid-β; (APP), amyloid-β protein
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ights reserved.to the onset and pathogenesis of this devastating disease is still
controversial.
There were 26.6 million cases of AD in the world in 2006 and it was
projected that the worldwide prevalence of AD will grow fourfold to
106.8 million with 1 in 86 people living with AD by the year 2050 [2].
The increase is a result of the aging population worldwide which
signiﬁes the fact that AD is a disease of aging and aging represents the
single biggest risk factor for AD. Increased oxidative stress has been im-
plicated in the agingprocess. Oxidative stress is the redox state resulting
from an imbalance between the generation and detoxiﬁcation of
reactive oxygen species (ROS). ROS are unavoidable physiological
byproducts which act as a double-edged sword in the biological system
[3]: they can serve crucial functions such as signaling molecules under
carefully controlled situations, but can do damage to the biological sys-
tem when present in excess amount since they are capable of oxidizing
all major biomolecules including nucleic acid (DNA, RNA), protein, and
lipids. The brain is highly susceptible to oxidative imbalance due to its
high energy demand, high oxygen consumption, rich abundance of eas-
ily peroxidizable polyunsaturated fatty acids, high level of potent ROS
catalyst iron, and relative paucity of antioxidants and related enzymes.
It is no wonder that oxidative imbalance and subsequent oxidative
stress mediated damage to biomolecules are extensively reported in
AD and increasing evidence suggest that oxidative imbalance plays a
critical role in the disease [4]. As the main source of ROS generation
and also a major target of oxidative damage, progressive impairment
of mitochondrial function has also been implicated in aging and AD
[5]. The interaction between oxidative stress and mitochondrial
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deﬁcits and likely plays an important role in the pathogenesis of AD.
2. Evidence of oxidative stress in Alzheimer's disease
ROS are generated under normal conditions and their levels are kept
relatively low by the delicate balance between the rate of their produc-
tion and the rate of their clearance by antioxidant and related enzymes.
Thus, either enhanced ROS production or impaired antioxidant system
will tip the cellular redox balance to oxidative imbalance and cause
ROS overproduction. ROS are usually highly reactive, unstable and have
a very short half-life, thus making them difﬁcult to measure directly.
Oxidized biomolecule products generated by ROS are much more stable
and commonly used as ROS markers. In addition, ROS could also be
assessed indirectly by measuring antioxidant levels or antioxidant en-
zyme activity. In fact, oxidative imbalance and signiﬁcant increase of its
by-products have been consistently reported in AD.
2.1. Lipid peroxidation
A large body of research has demonstrated that lipid peroxidation is
greatly enhanced in AD. Lipid peroxidation refers to the process in
which lipids are attacked by ROS through a free radical chain reaction
mechanism to generate lipid peroxidation products. By far, themost ex-
tensive lipid peroxidation products studied in ADare reactive aldehydes
including 4-hydroxynonal, malondialdehyde (MDA), and 2-propenal
(acrolein), and chemically and metabolically stable isoprostanoids
including F2-isoprostanes and F4-neuroprostanes. It was reported that
the 4-hydroxynonal levels are signiﬁcantly elevated in hippocampus
[6–8], entorhinal cortex [8], temporal cortex [8], amygdala [6,7],
parahippocampal gyrus [7], ventricular ﬂuid [9], and plasma [10] in
AD patients compared with age-matched control subjects. Signiﬁcant
increase of MDAwas also reported in hippocampus [6], pyriform cortex
[6], temporal cortex [11,12], occipital cortices [13], and erythrocytes
[14] from AD patients. Several studies found no change of basal MDA
[15–19] but signiﬁcant higher stimulated MDA production in various
AD brain regions [15,18]. In addition, acrolein, the most reactive
of the α,β-unsaturated aldehydes, was found to be elevated in AD
hippocampus/parahippocampal gyrus [20–22], amygdala [21], superior
and middle temporal gyri [22], and cerebellum [22]. F2-isoprostanes
and F4-neuroprostanes are stable products generated from peroxida-
tion of arachidonic acids and docosahexaenoic acid, respectively. Their
levels were found to be signiﬁcantly increased in frontal/temporal
poles [23], cerebrospinal ﬂuid [24–26], urine [26], and plasma [26] of
AD patients.
2.2. Protein oxidation
Oxidativemodiﬁcations of proteins, resulting either from direct ROS
attack, or from the reaction with glycation, glycoxidation, and lipid per-
oxidation product binding, have also been extensively reported in AD.
The most widely studied markers of protein oxidation are protein car-
bonyls and 3-nitrotyrosine. A signiﬁcant increase of protein carbonyl
content was reported in hippocampus [27,28], parietal lobe [17], and
superior middle temporal gyri in AD patients [28]. However, it still re-
mains controversial whether there is elevation of overall brain carbonyl
levels in AD [16,17,29]. Signiﬁcant increase of the carbonyl level of spe-
ciﬁc proteins such as creatine kinase, glutamine synthase, and ubiquitin
carboxy-terminal hydrolase L-1 was detected in different AD brain re-
gions including hippocampus, frontal and temporal lobes, inferior pari-
etal lobe, and cerebellum [28,30–32]. The other major protein oxidative
modiﬁcation, 3-nitrotyrosine, is the end product of the interaction of
peroxynitrite with tyrosine residues and was found to be signiﬁcantly
increased in AD in various brain regions [32–38] and cerebrospinal
ﬂuid [35].2.3. DNA/RNA oxidation
Numerous studies have provided evidence that oxidative damage of
DNA/RNAwas increased in AD. Oxidative damage of DNA can causeDNA
double strand breaks, DNA/DNA or DNA/protein crosslinking, and base
modiﬁcation. High levels of DNA breaks were found in both AD hippo-
campus [39] andAD cerebral cortex [40]. Themostwidely used DNA ox-
idative markers in AD are 8-hydroxydeoxyguanosine (8-OHdG) and 8-
hydroxyguanosine (8-OHG), which is the product of guanine oxidation.
Guanine is the base most readily attacked by oxidative stress due to its
low oxidation potential compared with the other three DNA bases. AD
brains demonstrated signiﬁcant increase of 8OHdG and 8-OHG in both
mitochondrial DNA and nuclear DNA compared with age-matched con-
trols [33,41]. RNA is largely single stranded and is usually subjected to
similar oxidative damage/modiﬁcations as DNA. Predominant oxidation
of cytoplasmic RNA rather than nuclear DNA was reported in AD [42].
Signiﬁcant higher levels of oxidized rRNA or mRNAs were also docu-
mented in AD [43–45].
2.4. Antioxidants
In addition to the widespread increase of oxidative biomolecule
products, signiﬁcant decrease of antioxidant levels or antioxidant en-
zyme activity has been repetitively reported. The plasma levels of anti-
oxidants such as albumin, bilirubin, uric acid, lycopene, vitamin A,
vitamin C, and vitamin E were found to be decreased in AD patients
[46,47]. Signiﬁcant decrease in the activity of antioxidant enzymes
such as superoxide dismutase, catalase, glutathione peroxidase, and
heme oxygenasewas also reported in different AD brain areas including
frontal and temporal cortices, although the expression levels of some of
them were increased [12,48–50].
3. Oxidative stress as an early event in Alzheimer's disease
It is known that ADhas a long latent period before symptoms appear
and a diagnosis can be made. Recent studies demonstrated that the
onset of AD is commonly preceded by an interim phase known as
mild cognitive impairment (MCI), when there is no signiﬁcant increase
of senile plaques and NFTs [51–53]. Indeed, MCI subjects exhibited sig-
niﬁcant oxidative imbalance compared with age-matched controls. For
example, the levels of the isoprostane 8,12-iso-iPF2α-VI were signiﬁ-
cantly increased in cerebrospinal ﬂuid, plasma, and urine of MCI sub-
jects compared with age-matched control subjects, whereas the levels
of AD cerebrospinal ﬂuid markers such as Aβ or tau remained un-
changed [54]. Enhanced overall protein peroxidation as well as oxida-
tive modiﬁcation of speciﬁc proteins were also found in hippocampus
and superior andmiddle temporal gyri fromMCI subjects [55,56]. Previ-
ous andmore recent studies showed signiﬁcant decreased levels of non-
enzymatic antioxidants such as uric acid, vitamin C, vitamin E, vitamin
A, lutein, zeaxanthin, β-cryptoxanthin, andα-carotene, and reduced ac-
tivity of antioxidant enzymes such as superoxide dismutase, glutathione
peroxidase, and glutathione reductase in MCI patients [57,58]. Since
MCI subjects are at high risk to progress to early AD and thewidespread
oxidative damage in MCI could precede the pronounced AD neuropath-
ological alterations, these facts strongly suggest that oxidative imbal-
ance appears at the very early stage of AD and is probably a central
feature of the pathogenesis of AD. In fact, it was also reported that
lipid peroxidation product, isoprostane 8,12-iso-iPF2alpha-VI, is in-
creased in the urine, blood, and cerebrospinal ﬂuid of AD patients and
correlated with the severity of the disease [26], further suggesting that
oxidative stress also plays an important role in the progression of the
disease.
Patients with DS, caused by trisomy of chromosome 21 and charac-
terized by enhanced Aβ production in the brain and increased incidence
of developing AD inmiddle age [59], demonstrated predictable progres-
sion of AD-type pathology with age. Signiﬁcant oxidative stress occurs
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marks such as senile plaques and NFTs [4,60–62]. In vitro cultured DS
neurons derived from fetal DS also demonstrated higher levels of ROS
and signiﬁcant oxidative damage [63]. The results that ROS overproduc-
tion preceded neuronal death, and that antioxidants could greatly en-
hance neuronal viability, strongly suggested that DS neurons had a
preset oxidative imbalance, which was probably responsible for neuro-
nal deﬁcits and subsequent pathological changes during the progression
of DS.
Depending on the stability of oxidation modiﬁcation products, two
distinct distribution patterns of oxidative modiﬁcation were revealed
by detailed in situ studies: products of lipid peroxidation or protein
glycation often cause crosslinked molecules which are resistant to deg-
radation at the site of generation. These modiﬁcations likely represent
cumulative oxidative damage during the course of the disease. In situ
detection of thesemodiﬁcations indicates that theywerewidely present
in neurons with and without associated pathology [34,64,65]. On the
contrary, oxidized DNA/RNAs are rapidly turned over, the levels of
which likely reﬂect steady state oxidative stress. However, RNA oxida-
tion is prominent in cells without pathology but less abundant in
neurons with pathology in AD brain [42,66–68]. These data suggest
that oxidative stress occurs earlier than, and likely contributes to the
formation of AD-associated pathology and furthermore, AD-associated
pathology may play a protective role in quenching ROS production.
Such a notion is also supported by studies in DS patients where oxida-
tive stress gradually decreased when amyloid pathology increased
with age [69]. Nevertheless, onemost recent live imaging study demon-
strated active ROS production followed by neuronal death in the prox-
imity to amyloid plaques in the brain of APP/PS1 transgenic mice [70].
Whether this observation can be directly translated into the human sit-
uation is unclear sincemany therapeutics effective in ADmousemodels
failed to have any clinical beneﬁt in human patients. Overall, these stud-
ies suggest that oxidative stress is not only an early event during the
course of the disease, but also precedes the AD pathology which sug-
gests a central role of oxidative stress in the pathogenesis of AD.
Evidence further supporting the causative role of oxidative imbal-
ance in the pathogenesis of AD comes from studies showing that antiox-
idant vitamin deﬁciency alone is sufﬁcient to induce neurological
deﬁcits similar to those in AD. For example, it has been extensively re-
ported that the deﬁciency of vitamin E, one of the most important fat-
soluble antioxidants, caused dementia and other neurological symp-
toms with an increased risk of developing AD [71,72], and the addition
of vitamin E could reverse the neurologic dysfunction [72]. In addition
to vitamin E, the deﬁciencies of other vitamins that have antioxidant ac-
tivity were also reported to impair brain function. The lack of folate, a
water-soluble vitamin B9 that is important for the development and
normal function of the central nervous system [73], resulted in cognitive
decline, dementia, depression and other neurological symptoms
[74,75]. And, the treatment with folic acid could signiﬁcantly alleviate
neurological deﬁcits in those folic acid deﬁciency patients [76]. Demen-
tia, cognitive impairment and other AD like neurological symptoms
have also been found in subjects with vitamin B12 [77] and vitamin D
deﬁciency [78]. Taken together, these ﬁndings suggest that oxidative
imbalance is an early event and likely plays an important role in the
pathogenesis of AD.
4. Mitochondrial dysfunction and oxidative stress in
Alzheimer's disease
Mitochondria are the major source of oxidative stress because the
unavoidable electron leakage during electron transfer leads to the con-
stant production of superoxide anion which, despite the presence of an
efﬁcient mitochondrial/cellular antioxidant system, is responsible for
90% of the endogenous ROS. It is suggested that dysfunctional mito-
chondria are less efﬁcient producers of ATP butmore efﬁcient producers
of ROS, which could represent a major source of oxidative imbalanceobserved in AD [79,80]. Indeed, mitochondrial dysfunction is a promi-
nent and early feature of AD [81], and almost all aspects ofmitochondri-
al function have been reported to be impaired in AD.
4.1. Reduced energy metabolism
Reduced energy metabolism in the diseased brain is one of the best
documented abnormalities in AD. In fact, low glucose metabolism at
baseline and longitudinal glucose metabolism decline are viewed as
sensitive measures useful for monitoring change in cognition and func-
tionality in AD andMCI, and are being increasingly adopted to assist di-
agnosis and used to predict future cognitive decline [82–84].
4.2. Alterations in the key enzymes in oxidative phosphorylation
A genome-wide transcriptomic study suggests that cerebral glucose
metabolic decline in AD is associated with reduced neuronal expression
of nuclear genes encoding subunits of themitochondrial electron trans-
port chain. Indeed, several key enzymes of oxidativemetabolism includ-
ing α-ketoglutarate dehydrogenase complex, pyruvate dehydrogenase
complex, and cytochrome oxidase all demonstrated reduced expression
and/or activity in AD [80,85–90], alteration of which signiﬁcantly corre-
lated with clinical state and plaque counts [91]. Increased oxidative
stress likely caused further reduction in activity of some of these en-
zymes such as that of α-ketoglutarate dehydrogenase complex.
4.3. Calcium dyshomeostasis
Dysfunctional mitochondria contribute to calcium dyshomeostasis
through impaired buffering capacity or direct impact on the endoplas-
mic reticulum calcium channels [92]. Indeed, calcium mishandling
was reported inperipheral cells fromADpatients such that endoplasmic
reticulum (ER) develops calcium overload and calcium uptake is dimin-
ished [93,94]. Indirect evidence suggests elevated intracellular calcium
inADbrain since calmodulin-dependent kinase and calpain are elevated
in vulnerable neurons early in the disease process [95–98]. Most
recently, it was demonstrated that the function of mitochondria-
associated ER membranes and ER–mitochondrial communication are
increased signiﬁcantly in ﬁbroblasts frompatientswith both the familial
and sporadic formsof AD [99]. Consistently, increased expression of sev-
eral ER–mitochondria interface proteinswas also reported in early stage
of AD [100]. These suggest that altered mitochondria-associated mem-
brane (MAM) will likely contribute to calcium dyshomeostasis and mi-
tochondrial dysfunction.
4.4. Mitochondrial DNA (mtDNA)
Elevated levels of sporadic mutations in the mtDNA including the
most common 5-kb deletion were demonstrated in the brain of AD pa-
tients [101,102]. In fact, several of the mutations in the mtDNA control
regions were unique to AD [103–106]. Due to the absence of protective
proteins such as histone, the relative paucity of efﬁcient DNA repair sys-
tem and the close proximity to site of ROS generation,mtDNA is vulner-
able to ROS attack. Analysis of oxidized nucleoside revealed three-fold
increase in oxidative damage in the mtDNA in AD brain [41], which
probably is the cause of the increased mutations. Consistent with the
systemic increase of oxidative stress, mutations in mtDNA were also
found in blood samples from AD and lymphoblastoid lines derived
from AD blood samples. Many of these mutations occur at sites of
known mtDNA transcription and replication regulatory element and
thus cause reduced transcript levels of crucial mitochondrial proteins
that is deleterious to mitochondrial function [103,107]. A causal role of
mtDNA alterations in some of AD-related deﬁcits such as oxidative
stress and biochemical deﬁcits in cytochrome oxidase activity and calci-
um handling were demonstrated in cybrids where mtDNA from AD pa-
tients were transferred into cell lines devoid of mtDNA [108].
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Mitochondria lie in the center of the intrinsic apoptotic pathway.
Although it remains controversial whether apoptosis plays a major
role in neurodegeneration in AD [109], it is clear thatmany components
of the intrinsic apoptotic pathway are activated or altered in AD brain
[110]. It is of interest to note that the activation of these molecules
may not necessarily lead to apoptosis. For example, it appears that cas-
pase 3 is cleaved and activated in ADwhich is linked to tau cleavage and
NFT formation [111].
5. Abnormal mitochondrial dynamics and oxidative stress in
Alzheimer's disease
The normal function of mitochondria is dependent upon their intact
structure to keep the proper electrochemical gradient. Structurally
damaged mitochondria, as evidenced by broken cristae and partial or
near complete loss of the internal structure, were abundant and repre-
sent a prominent feature in vulnerable neurons in biopsied AD brain
as revealed by electron microscopy [101], which is likely the structural
basis of the signiﬁcantmitochondrial dysfunction in AD. A slight but sig-
niﬁcant increase in mitochondrial size along with a signiﬁcant decrease
in mitochondrial number in these neurons was noted [101]. The size
and number of mitochondria are regulated by the dynamic process of
mitochondrial ﬁssion and fusion [112], therefore, this study was the
ﬁrst that implicated the involvement of abnormal mitochondrial dy-
namics in AD.
Mitochondria are highly dynamic organelles that undergo continual
ﬁssion and fusion eventswhich regulate themorphology anddistribution
of mitochondria [113]. Mitochondrial ﬁssion and fusion are regulated by
mitochondrial ﬁssion proteins such as dynamin-like protein 1 protein
(DLP1, also referred to as DRP1), Fis1 [114,115], andMff [116], andmito-
chondrial fusion proteins such asmitofusin 1 (Mfn1),mitofusin 2 (Mfn2),
and optic atrophy protein 1 (OPA1) [114,115]. The majority of DLP1 re-
side in the cytoplasm. However, during ﬁssion, DLP1 is recruited to the
mitochondrial surface and appears as punctate spots. Fis1, Mff, Mfn1,
and Mfn2 are mitochondrial transmembrane proteins localized to the
outer mitochondrial membrane [117,118], while OPA1 is localized to
the inner mitochondrial membrane. In support of the involvement of
altered mitochondrial dynamics in AD, recent studies demonstrated sig-
niﬁcant changes in the expression of almost all mitochondrial ﬁssion and
fusion proteins including DLP1, OPA1, Mfn1/2, and Fis1 in the brain from
AD patients [119–123]. Mitochondrial DLP1, the fraction critical forFig. 1.Mitochondrial dysfunction is likely involved in the initiation and/or ampliﬁcation of oxi
negatively impact mitochondrial integrity and function. Defects in mitochondrial dynamics, e
will makemitochondria less versatile in responding to the changing needs of neurons whichw
dysfunction and ensuing greater oxidative stress and their interactions have the potential to for
tion, insufﬁcient compensation and degeneration in AD.mitochondrial ﬁssion, is increased in AD brain [119]. Consistently, DLP1
phosphorylation at Ser616 and S-nitrosylation of DLP1, which either fa-
cilitate DLP1 translocation tomitochondria or activate theGTPase activity
of DLP1 and thus facilitatemitochondrial ﬁssion, are also increased in AD
[119,124]. Interestingly, DLP1 interacts with Aβmonomer and oligomers
and phosphorylated tau in AD brain tissues [121,125], although it
remains to be determined how such interactions may impact mitochon-
drial dynamics.More detailed analysis revealed signiﬁcantly reducedmi-
tochondrial length but increased mitochondrial width with a signiﬁcant
increase in overall size that resulted in a rounder and fatter (i.e., swollen)
morphology of mitochondria in vulnerable neurons from biopsied AD
brains [126]. Although larger mitochondria are normally the result of
inhibited ﬁssion or enhanced fusion, similarly swollen mitochondria
were abundant in the brain of fusion-deﬁcient Mfn2 knockout mice
[127]. While admittedly non-conclusive due to the “snap-shot” nature
of the morphometric study based on electron microscopy micrographs,
considering the biochemical data, these studies collectively suggested
that there is likely enhanced ﬁssion which leads to structurally damaged
and swollen mitochondria in vulnerable neurons in the AD brain. Such a
notion is supported by in vitro and animalmodels of AD [128]. For exam-
ple, neurons treated with oligomeric Aβ or overexpressing familial
AD-causing mutant APP demonstrate mitochondrial fragmentation and
structural damages [119,126,129]. Feany's group demonstrated that tau
overexpression causes mitochondrial elongation in Drosophila through
actin-stabilization mediated DLP1 mislocalization [130], however, over-
expression of caspase cleaved tau or tau hyperphosphorylation (i.e., car-
dinal features of human tauopathies including AD) causes mitochondrial
fragmentation inmammalian cells [131–135]. Damaged and swollenmi-
tochondria are also documented in the brain of Tg2576 andAPP/PS1mice
[136]. Interestingly, the 3-dimension reconstruction of consecutive
electron micrographs revealed the presence of swollen mitochondria
connected by very narrow membrane segments resembling “beads-on-
the-string” pattern in these AD mouse models [136]. This peculiar
“beads-on-the-string” pattern may reﬂect enhanced ﬁssion caught in
action before the ﬁnal scission or enhanced ﬁssion with arrested ﬁnal
scission, the distinction of which requires techniques that can overcome
the snap-shot nature of an electron microscopy study such as in vivo
imaging on live animals.
While it remains to be determined whether and how excessive ﬁs-
sion causes structural damage to mitochondria in AD, it is clear that ex-
cessive ﬁssion is sufﬁcient to causemanydeleterious consequences seen
in AD including increased oxidative stress [137]. It was reported that
ROS was overproduced along with mitochondrial fragmentation whendative stress during the onset and progression of Alzheimer disease. Oxidative stress can
ither due to the response to genetic deﬁcits or metabolic or environmental alterations,
ill exacerbate mitochondrial dysfunction in chronic condition. The resultant mitochondrial
m a vicious downward spiral that becomes a ubiquitous causative feature of cell malfunc-
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inhibition of mitochondrial pyruvate uptake, an effective means to
stop ROS increase, did not prevent mitochondrial fragmentation while
genetic inhibition ofmitochondrial ﬁssion by dominant negativemutant
form of DLP1 prevented ROS production in high glucose conditions, sug-
gesting that mitochondrial fragmentation plays a critical role in ROS
overproduction and oxidative imbalance [137]. More recently, we and
others demonstrated that mitochondrial electron-transport-chain com-
plex inhibitors such as rotenone, 1-methyl-4-phenylpyridinium, and
3-nitropropionic acid cause fragmentation of the mitochondrial net-
work along with increased ROS production [138–140]. Antioxidants
could only partially alleviate electron-transport-chain complex inhibitor
induced mitochondrial fragmentation [139,140], while inhibition of mi-
tochondrial ﬁssion could signiﬁcantly reduce ROS overproduction and
block mitochondrial/cellular dysfunction [140], further suggesting that
mitochondrial function and dynamics are intimately related, and mito-
chondrial morphological dynamics are essential for the maintenance of
ROS balance. Indeed, ROS overproduction in AD models could be efﬁ-
ciently prevented or rescued by the inhibition of mitochondrial ﬁssion
or the promotion of mitochondrial fusion, demonstrating the contribu-
tion of abnormal mitochondrial dynamics to oxidative imbalance in AD
[119,122,126,141]. Defects in mitochondrial ﬁssion and fusion can also
increase ROS indirectly through negative impact on bioenergetics,
calcium handling, and mtDNA integrity. For example, mitochondrial ﬁs-
sion plays a crucial role in the assembly of electron transport complexes
and controls the dynamic features ofmitochondrial nucleoids [142,143].
Unopposed ﬁssion leads to rapid accumulation ofmtDNAmutations and
decreased calcium buffering capacity [144,145]. The balance of mito-
chondria ﬁssion and fusion is also sensitive to oxidative imbalance.
Most recent studies demonstrated that, through regulation ofmitochon-
drial ﬁssion and fusion proteins such as DLP1 and Mfn2, both endoge-
nous [146] and exogenous [147] applications of ROS might directly
impair mitochondrial ﬁssion and fusion balance, induce mitochondrial
fragmentation and further cause subsequent mitochondrial dysfunction
including ROS overproduction and thus form a vicious cycle that am-
pliﬁes oxidative stress which perhaps plays an important role in the ox-
idative imbalance in AD.
6. Conclusion
The importance of oxidative stress in the pathogenesis of AD is sup-
ported by the early occurrence and the widespread nature of oxidative
damages in AD. Increased oxidative stress also characterizes the aging
process. However, that oxidative stress is signiﬁcantly increased in the
AD brain compared to age-matched elderly controls indicates that AD
is not a normal part of aging which thus suggests that additional factors
must be involved in initiating and/or amplifying oxidative stress during
the onset and progression of the disease. Among many potential initia-
tors/sources, mitochondria likely play a critical, if not central, role be-
cause of their primacy in energy metabolism and redox homeostasis.
Defects inmitochondrial dynamics, either due to the response to genet-
ic deﬁcits or metabolic or environmental alterations, will make mito-
chondria less versatile in responding to the changing needs of cells
which likely have particularly debilitating effects on neurons. The resul-
tant mitochondrial dysfunction and ensuing oxidative stress and their
interactions have the potential to form a vicious downward spiral that
becomes a ubiquitous causative feature of cell malfunction and degen-
eration (Fig. 1). Clearly, more studies are needed to understand the ini-
tiation of oxidative stress and the critical contribution of mitochondrial
dysfunction in AD.
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